Drug reference

Bevacizumab

Anti-VEGF-A humanised monoclonal antibody · Antineoplastic

Also known as Avastin, Mvasi, Zirabev, Abevmy

START

Regimen-specific (e.g. 5–10 mg/kg q2w or 7.5–15 mg/kg q3w with chemo); hold ≥28 days around major surgery

TYPICAL MAX

Regimen-defined (up to 15 mg/kg q3w)

STOP IF

GI perforation, serious haemorrhage, arterial thromboembolism, hypertensive crisis, nephrotic syndrome

WATCH

BP each visit, urine protein, bleeding/GI symptoms, wound healing, thromboembolism

CDSCO approvedSchedule HATC L01FG01

Dose laddermg/d

Renal dose adjustmenteGFR mL/min/1.73m²

KDIGO 2024 + manufacturer label

Pharmacokineticsplasma · t hours

ONSET: 30min · absorption onset
PEAK: 2h · end of infusion
t½: 2.9w · terminal t½ (~20 days)
DURATION: 2w · q2-week interval

EXCRETION

Proteolytic catabolism; not renal

route + CYP

INTERACTIONS

6 major

incl. contraindicated

PREGNANCY

Avoid — embryo-fetal harm (impaired angiogenesis); contraception during and ≥6 months after

FDA category + note

Top interactionssee all 8 →

Live VaccinesContraindicatedDatabaseKimi deep-research + Cla
AnticoagulantsSevereDatabaseKimi deep-research + Cla
DeferiproneSevereDatabaseDDInter
PanitumumabSevereDatabaseKimi deep-research + Cla

Available in India

36 branded formulations. Look up specific brands in the Drugs workspace.

Mechanism

Binds and neutralises vascular endothelial growth factor A, preventing VEGFR activation → inhibits tumour angiogenesis, normalises vasculature and reduces interstitial pressure; antiangiogenic across multiple solid tumours.

Indications

Metastatic colorectal cancerNon-squamous NSCLC, metastatic renal cell carcinomaRecurrent glioblastomaEpithelial ovarian/fallopian/peritoneal and cervical cancerNeovascular age-related macular degeneration (off-label intravitreal)

Dosing

Adult: Regimen-specific IV: e.g. 5–10 mg/kg every 2 weeks or 7.5–15 mg/kg every 3 weeks depending on tumour/combination.
Pediatric: Not established (selected protocols).
Renal adjustment: No adjustment (antibody); monitor proteinuria.
Hepatic adjustment: No specific adjustment.
Geriatric: Higher arterial thromboembolism risk; monitor.
Max dose: Regimen-defined (up to 15 mg/kg q3w)

Pharmacokinetics

Onset

Antiangiogenic over days–weeks

Peak effect

End of infusion

Duration

q2–3 week dosing

Half-life

~20 days

Bioavailability

100% IV

Protein binding

Not applicable (antibody)

Metabolism

Proteolytic catabolism

Excretion

Not renally excreted

Contraindications

Recent haemoptysis/serious haemorrhage
GI perforation/fistula history (relative)
Untreated CNS metastases with bleeding risk
Within 28 days of major surgery / non-healing wound
Hypersensitivity to bevacizumab

Side effects

Common

HypertensionProteinuriaEpistaxis, headacheFatigue, diarrhoea

Serious

GI perforation/fistula
Serious haemorrhage (incl. pulmonary, CNS)
Arterial/venous thromboembolism
Wound-healing complications
Hypertensive crisis; nephrotic syndrome; posterior reversible encephalopathy; ovarian failure